JZT(000989)2024-04-24 13:24Financial Performance - The company's revenue for Q1 2024 was ¥1,079,482,203.93, a decrease of 0.89% compared to ¥1,089,123,621.24 in the same period last year[5] - Net profit attributable to shareholders decreased by 10.66% to ¥144,601,666.94 from ¥161,848,803.83 year-on-year[5] - The company experienced a 10.68% decline in basic and diluted earnings per share, which fell to ¥0.1689 from ¥0.1891[5] - Net profit for the current period is ¥144,417,064.21, down 10.59% from ¥161,584,258.51 in the previous period[22] - Operating profit decreased to ¥178,562,130.17, a decline of 11.00% from ¥200,479,163.56 in the previous period[22] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥302,402,236.01, a decline of 134.15% compared to -¥129,146,639.74 in the previous year[5] - Cash flow from operating activities showed a net outflow of ¥302,402,236.01, compared to a smaller outflow of ¥129,146,639.74 in the previous period[24] - Cash and cash equivalents decreased to CNY 296,751,829.80 from CNY 672,713,939.53, a decline of about 55.9%[17] - Cash and cash equivalents at the end of the period decreased to ¥296,751,829.80 from ¥820,024,973.68 in the previous period[25] Assets and Liabilities - Total assets increased by 7.51% to ¥5,730,017,623.90 from ¥5,329,798,977.51 at the end of the previous year[5] - The total liabilities increased to CNY 1,638,283,894.09 from CNY 1,382,482,311.91, reflecting a rise of about 18.5%[18] - The company's total current assets rose to CNY 3,344,837,404.29 from CNY 2,919,348,115.41, representing an increase of about 14.6%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 54,662[11] - The largest shareholder, Li Zhenguo, holds 25.17% of the shares, amounting to 215,398,371 shares, with 126,653,871 shares pledged[11] - Heilongjiang Cheneng Gongda Venture Investment Co., Ltd. holds 17.79% of the shares, totaling 152,230,587 shares[11] - Hunan Yifeng Pharmaceutical Co., Ltd. owns 4.99% of the shares, equivalent to 42,710,000 shares[11] - The top ten shareholders include various entities, with the largest three holding a combined total of 392,337,955 shares, representing a significant portion of the company's equity[11] Operational Metrics - Accounts receivable increased by 91.08% to ¥84,410.28 million, primarily due to increased sales during the period[8] - The company reported a significant increase in prepayments, which rose by 187.45% to ¥8,465.40 million[8] - Total operating costs increased to ¥928,718,084.94, up 2.93% from ¥904,879,884.39 in the previous period[20] - Research and development expenses increased to ¥31,431,947.80, up 10.00% from ¥28,361,880.45 in the previous period[20] Financial Adjustments and Issues - The company has acknowledged a financial misstatement related to the use of non-company bank accounts for receiving sales deposits, which does not significantly affect its main financial data[15] - The company reported a non-operating fund occupation of CNY 37 million from March to October 2022, which has since been resolved[16] Future Outlook - Future strategies and product developments were not detailed in the report[11] - The report indicates that there are no significant changes in the shareholding structure compared to the previous period[11] - The company has not engaged in any mergers or acquisitions during the reporting period[11]